Voisard Asset Management Group Inc. Purchases 35 Shares of Amgen Inc. (NASDAQ:AMGN)

Voisard Asset Management Group Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 235 shares of the medical research company’s stock after acquiring an additional 35 shares during the period. Voisard Asset Management Group Inc.’s holdings in Amgen were worth $76,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AMGN. Strategic Financial Concepts LLC purchased a new stake in Amgen during the second quarter valued at about $26,000. Hershey Financial Advisers LLC purchased a new stake in Amgen during the second quarter valued at about $30,000. nVerses Capital LLC purchased a new stake in Amgen during the second quarter valued at about $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen during the second quarter valued at about $33,000. Finally, Matrix Trust Co purchased a new stake in Amgen during the third quarter valued at about $36,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on AMGN shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 target price (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and set a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 target price on shares of Amgen in a report on Tuesday, October 22nd. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a report on Thursday, September 26th. Finally, Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $332.55.

Amgen Trading Down 0.1 %

NASDAQ:AMGN opened at $315.54 on Thursday. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The business has a fifty day moving average price of $324.75 and a 200-day moving average price of $314.78. The firm has a market capitalization of $169.27 billion, a price-to-earnings ratio of 45.08, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.96 earnings per share. Sell-side analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.